title: Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial.
abstract: BACKGROUND
  Third-generation rotary blood pumps have magnetically levitated rotors that eliminate mechanical wear over the years. Together with their potential for miniaturization, these pumps seem suitable for long-term support of patients with a wide range of body surface areas (BSA). Recently, the novel HVAD pump (HeartWare Inc, Framingham, MA), a miniaturized centrifugal pump with a hydrodynamic, magnetically levitated rotor, became ready for clinical application.
  
  
  METHODS
  In a multi-institutional trial in Europe and Australia, 23 patients (mean age, 47.9 ± 12 years) in end-stage heart failure were enrolled in 5 centers. The primary end point of the bridge-to-transplant study was survival to heart transplant or survival to 180 days on the device, whichever occurred first. Follow-up data at 1 year are presented. The small size of the device allows for intrapericardial placement of the pump.
  
  
  RESULTS
  Implant procedures were generally fast and uneventful. Mean duration of support was 167 ± 143 days (range, 13-425 days), and mean blood flow provided by the pump was 6.1 ± 1.1 liters/min. At the 180-day end point, 2 patients had undergone successful transplant at 157 and 175 days, 2 patients died while on the device, and 19 patients continued pump support for more than 180 days. Actuarial survival after 6 months was 91% and was 86% at the 1-year follow-up.
  
  
  CONCLUSIONS
  The design of the HVAD pump enables a quick and less invasive implantation. The results to date demonstrate satisfactory long-term survival with excellent quality of life in this cohort of 23 patients of the initial multi-institutional Conformité Européene (CE) mark trial.
authors.affiliation: Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18-20, Vienna, Austria. georg.wieselthaler@meduniwien.ac.at
authors.forename: Georg M
authors.initials: GM
authors.lastname: Wieselthaler
authors.forename: Gerry
authors.initials: G
authors.lastname: O Driscoll
authors.forename: Paul
authors.initials: P
authors.lastname: Jansz
authors.forename: Asghar
authors.initials: A
authors.lastname: Khaghani
authors.forename: Martin
authors.initials: M
authors.lastname: Strueber
mesh_terms: D000328:Adult; D001315:Australia; D004867:Equipment Design; D005060:Europe; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000628:therapy*; D016027:Heart Transplantation; D006353:Heart-Assist Devices / Q000009:adverse effects; D006801:Humans; D008280:Magnetics; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome